ERAS and gastric cancer: Bumetanide was found to potentially play a role in GC by targeting ERAS (ES cell expressed Ras) genes, while nystatin may play a role in GC by targeting SST (somatostatin) and ADRB3 (adrenoceptor Beta 3) genes (Fig. 18).